Barry Berger Discusses Cologuard

Video

Barry Berger, MD, Exact Sciences Corporation, discusses Cologuard, an at-home screening for colorectal cancer.

Barry Berger, MD, Exact Sciences Corporation, discusses Cologuard, an at-home screening for colorectal cancer.

Berger says the test is straightforward because it give a positive or negative answer, which is concluded by examining DNA and fecal hemoglobin in the sample that the patients provide. However, patients should know that Cologuard does not use inherited DNA for screening, but instead looks at changes in DNA that are a result of undergoing carcinogenisis.

Recent Videos
Image of Pattie Jakel, MN, RN, AOCN, in front of a blue watercolor Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
Anatomical diagram of a person with the gastrointestinal tract highlighted in orange

OS Benefit With T-DXd in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma

Chris Ryan
March 6th 2025
Article

T-DXd delivered an OS benefit for patients with unresectable or metastatic HER2-positive gastric and GEJ adenocarcinoma following trastuzumab-based treatment.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Image of a calendar with a thumb tack stuck on a day reading "20," and a stethoscope lying on the calendar, with an image of a clock overlaying

Opinion: Oncology Nurses Can Ease the Burden of Time Toxicity in Cancer Care

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
February 26th 2025
Article

Similar to financial toxicity, time toxicity can have a profound impact on a patient’s quality of life.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Illustration of a clipboard with the word "Guidelines" on top of the page, followed by a check list

NCCN Guideline Updates on ctDNA Stance in MCC and Colon, Rectal Cancer

Kyle Doherty
February 22nd 2025
Article

The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.

Image of a three-dimensional model of a gastrointestinal tract with a stethascope surrounding it in an arc shape.

Envafolimab Plus Suvemcitug and FOLFIRI Demonstrates Early Efficacy in CRC

Kyle Doherty
February 10th 2025
Article

Envafolimab plus suvemcitug and FOLFIRI showed early efficacy and manageable safety in MSS/pMMR colorectal cancer, according to phase 2 trial data.